In 2020, CEDBCAM-RI won its first competitive grant: MEPOGENSA, a collaboration with the Wellcome Sanger Institute on Group B Streptococcus in pregnant women and newborns.
1
First competitive grant
1
International partner · Wellcome Sanger Institute
2
Target populations · pregnant women and newborns
Funded research
Funded · 2020Collaborative research
MEPOGENSA
Molecular Epidemiology and Population Genomics of Streptococcus agalactiae Isolates from the Microbiome of Pregnant Women and Neonates
MEPOGENSA describes the burden and the phenotypic and genotypic characteristics of Streptococcus agalactiae (Group B Streptococcus) in pregnant women and newborns in Cameroon, including virulence factors and resistance mechanisms, to guide surveillance, prevention and control strategies.
Principal Investigator: Prof. Stephen Bentley, Wellcome Sanger Institute (United Kingdom)
Co-Principal Investigator (African collaborator): Dr Luria Leslie Founou (CEDBCAM-RI)
Funder: Cambridge-Africa ALBORADA Research Fund, University of Cambridge
Group B StreptococcusMaternal and neonatal healthPopulation genomics
What came next
In 2021, MEPOGENSA received a second grant from the RSTMH, alongside new grants for CAREFOOD and MOTION. See the 2021 projects →
Our 2020 partners and funders
Cambridge-Africa ALBORADA Research FundWellcome Sanger InstituteUniversity of Cambridge